Karen Jacks, MD
Hematology & Oncology · Las Vegas, NVNPI 1457577470
Payments from drug & device makers
Across 347 payments — averaging $126.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$30K
- Regeneron$5K
- Genentech, Inc.$3K
- Daiichi Sankyo Inc.$1K
- Exelixis Inc.$900
- Novartis$848
- plus $3K from 31 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 41 | $30,364 |
| Regeneron | 4 | $5,000 |
| Genentech, Inc. | 6 | $2,759 |
| Daiichi Sankyo Inc. | 104 | $1,360 |
| Exelixis Inc. | 28 | $900 |
| Novartis | 39 | $848 |
| Pfizer | 30 | $507 |
| Astellas Pharma US Inc | 7 | $186 |
| AstraZeneca(2 entities) | 9 | $178 |
| Bristol Myers Squibb | 7 | $153 |
| Sirtex Medical Inc | 1 | $146 |
| Beigene USA, Inc. | 5 | $140 |
| E.r. Squibb & Sons, L.L.C. | 6 | $136 |
| Tempus AI, Inc | 6 | $130 |
| GSK | 5 | $109 |
| Johnson & Johnson(2 entities) | 6 | $108 |
| Stemline Therapeutics Inc. | 6 | $105 |
| EMD Serono, Inc. | 5 | $98 |
| Array Biopharma Inc | 6 | $79 |
| Amgen | 4 | $75 |
| Beone Medicines USA, Inc. | 3 | $68 |
| Sanofi | 2 | $53 |
| AbbVie | 2 | $49 |
| Eisai Inc. | 2 | $40 |
| Sun Pharmaceutical Industries Inc. | 1 | $37 |
| Boehringer Ingelheim | 1 | $32 |
| Seagen Inc. | 1 | $24 |
| Incyte Corporation | 1 | $23 |
| Ipsen Biopharmaceuticals, Inc | 1 | $23 |
| Taiho Oncology, Inc. | 1 | $21 |
| Servier Pharmaceuticals LLC | 1 | $20 |
| Mirati Therapeutics, Inc. | 1 | $17 |
| Springworks Therapeutics, Inc. | 1 | $16 |
| Bayer | 1 | $15 |
| Puma Biotechnology, Inc. | 1 | $15 |
| Accord Healthcare, Inc. | 1 | $15 |
| Gilead | 1 | $12 |
How this compares
$43,864 in reported general payments places this provider in the 55th percentile of 82 hematology & oncology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Las Vegas
- Edwin KingsleyLas Vegas$9.2M
- Nicholas VogelzangLas Vegas$8.3M
- Oscar GoodmanLas Vegas$6M
- Khawaja JahangirLas Vegas$2.5M
- Carolyn MulroneyLas Vegas$1.5M
- Wolfram SamlowskiLas Vegas$1.1M
- Anuradha ThummalaLas Vegas$736K
- Grzegorz ObaraLas Vegas$668K
- Aaron GoodmanLas Vegas$480K
- Vikas GuptaLas Vegas$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.